公开(公告)号：US20240203593A1

公开(公告)日：2024-06-20

申请号：US18537992

申请日：2023-12-13

Applicant: IMMUNOBIOME INC.

Inventor： Seung Yeon CHOI ,  In Hae KIM ,  Jung Hwan PARK ,  Ju Hun LEE

IPC: G16H50/20 ,  G16B20/00 ,  G16B40/20

CPC classification number: G16H50/20 ,  G16B20/00 ,  G16B40/20

Abstract: The present invention aims to discover a microbial cluster that can be used when developing effective probiotics for a specific disease. Specifically, the invention includes (1) discovering a candidate microbial cluster data related to specific disease, which is collected by preprocessing a gut microbiota data (a taxonomy abundance table) and (2) training the machine learning model using the collected candidate microbial cluster data, and selecting a model with the highest predictive performance to discover a disease-microbial consortium.

公开(公告)号：US20240290455A1

公开(公告)日：2024-08-29

申请号：US18631165

申请日：2024-04-10

Applicant: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION ,  IMMUNOBIOME INC.

Inventor： Sang Uk KIM ,  Jung Ho KONG ,  In Hae KIM ,  Chang Wook Park

IPC: G16H20/17 ,  G16B20/30 ,  G16H50/70

CPC classification number: G16H20/17 ,  G16B20/30 ,  G16H50/70

Abstract: The present disclosure is to provide a biomarker-searching method that can predict responses to ICI treatment and overall survival of ICI-treated patients. When the device and the method according to the present disclosure are used, it is possible to detect a biomarker capable of accurately predicting effectiveness of ICI treatment on cancer patients and overall survival of the cancer patients. Accordingly, it is possible to maximize the effectiveness of ICI treatment.

公开(公告)号：US20240212786A1

公开(公告)日：2024-06-27

申请号：US18537930

申请日：2023-12-13

Applicant: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION ,  IMMUNOBIOME INC.

Inventor： Kwang Hwan LEE ,  Sang Uk KIM ,  In Hae KIM ,  Ju Hun LEE

IPC: G16B15/30 ,  G16B25/10

CPC classification number: G16B15/30 ,  G16B25/10

Abstract: In the present disclosure, the present inventors validated the effectiveness of the co-essentiality network, constructed from the gene essentiality profile across cancer cells, as a robust platform for identifying anticancer targets. Furthermore, the co-essentiality network facilitated the drug repurposing not previously addressed by conventional molecular networks. These findings underline the value of co-essentiality networks in advancing precision oncology, offering new potential therapeutic avenues.

公开(公告)号：US20240153635A1

公开(公告)日：2024-05-09

申请号：US18447458

申请日：2023-08-10

Applicant: IMMUNOBIOME INC. ,  POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION

Inventor： Sang Uk KIM ,  Min Hyuk Park ,  In Hae KIM ,  Chang Wook Park

IPC: G16H50/20 ,  G16B15/30 ,  G16B25/10 ,  G16H10/20 ,  G16H70/40

CPC classification number: G16H50/20 ,  G16B15/30 ,  G16B25/10 ,  G16H10/20 ,  G16H70/40

Abstract: According to the present disclosure, it is possible to predict a success or a failure of a clinical trial by reflecting the effect of a drug on a cell population and a human gene. Therefore, it is possible to solve the problems caused by excessive clinical trials, such as excessive use of the drug.